Study Interplay Between Asprosin with Vitamin D in Metabolic Syndrome

Abstract

Objective: The study aims to in investigating the role of the asprosin hormone and its relationship with Vitamin D in patients with metabolic syndrome and clinical parameters. Methods: The study included measurement asprosin hormone, Vitamin D, and some biochemical variable levels in metabolic syndrome patients with age matching to the control group (35–65 years). The study includes (95) samples of metabolic syndrome patients [49 female, 46 males] who were attending the abdominal consultation unit at the Ibn Sina Teaching Hospital in Mosul, Iraq. MetS were diagnosed in compliance with the criteria of the NCEP (ATP III) and AHA/NHLB. Samples were collected during the period from January 2021 to December 2021. Also, the study was carried out on 76 samples of apparently healthy (40 female, 36 male) as a control group. Results: The findings revealed a significant increase in the concertation of the asprosin hormone in metabolic syndrome patients compared to the control group. Also, it has been found that was a significant increase in the concertation of fasting glucose, insulin, homeostasis model for insulin resistance (HOMA-IR), Triglycerides, low-density lipoprotein-cholesterol, very low-density lipoprotein-cholesterol, total cholesterol and urea. In addition to a decline in high-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol (Non-HDL), (HOMA-B), Vitamin D and Calcium among metabolic syndrome patients. There is also a significant inverse correlation between asprosin hormone with the Vitamin D. Conclusion: The study concluded that the hormone asprosin is a good indicator that reflects the status of metabolic syndrome patients and Vitamin D appeared to be associated with MetS, as well as the Insulin resistance (IR) and lipid profile.